Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC
NCT00622193 is registered in ClinicalTrials.gov with Helsinn Therapeutics (U.S.), Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Anamorelin HCl Dose Range Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC
- Lead sponsor
- Helsinn Therapeutics (U.S.), Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2008
- Completion date
- December 31, 2009
- Enrollment
- 228 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.